CN104737170A - 多标记风险分层 - Google Patents

多标记风险分层 Download PDF

Info

Publication number
CN104737170A
CN104737170A CN201380054795.8A CN201380054795A CN104737170A CN 104737170 A CN104737170 A CN 104737170A CN 201380054795 A CN201380054795 A CN 201380054795A CN 104737170 A CN104737170 A CN 104737170A
Authority
CN
China
Prior art keywords
subject
age
risk
marker
risk score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380054795.8A
Other languages
English (en)
Chinese (zh)
Inventor
J.V.斯奈德
R.W.格温
S.雅各布森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Critical Care Diagnostics Inc
Original Assignee
Critical Care Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Critical Care Diagnostics Inc filed Critical Critical Care Diagnostics Inc
Priority to CN202010424423.1A priority Critical patent/CN111834009A/zh
Publication of CN104737170A publication Critical patent/CN104737170A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment

Landscapes

  • Medical Informatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Primary Health Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
CN201380054795.8A 2012-08-21 2013-08-21 多标记风险分层 Pending CN104737170A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010424423.1A CN111834009A (zh) 2012-08-21 2013-08-21 多标记风险分层

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261691706P 2012-08-21 2012-08-21
US61/691,706 2012-08-21
PCT/US2013/056020 WO2014031764A1 (en) 2012-08-21 2013-08-21 Multimarker risk stratification

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010424423.1A Division CN111834009A (zh) 2012-08-21 2013-08-21 多标记风险分层

Publications (1)

Publication Number Publication Date
CN104737170A true CN104737170A (zh) 2015-06-24

Family

ID=50148799

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380054795.8A Pending CN104737170A (zh) 2012-08-21 2013-08-21 多标记风险分层
CN202010424423.1A Pending CN111834009A (zh) 2012-08-21 2013-08-21 多标记风险分层

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010424423.1A Pending CN111834009A (zh) 2012-08-21 2013-08-21 多标记风险分层

Country Status (12)

Country Link
US (4) US20140058743A1 (https=)
EP (1) EP2888687B1 (https=)
JP (3) JP6450679B2 (https=)
CN (2) CN104737170A (https=)
AU (3) AU2013305829A1 (https=)
CA (1) CA2882303A1 (https=)
HK (2) HK1208092A1 (https=)
IN (1) IN2015DN01767A (https=)
MX (2) MX375520B (https=)
RU (1) RU2015110054A (https=)
SG (2) SG10201608854TA (https=)
WO (1) WO2014031764A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220399122A1 (en) * 2019-11-01 2022-12-15 Nec Corporation Risk prediction apparatus, risk prediction method, and computer program

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
DK3072978T3 (en) 2002-05-09 2018-09-17 Brigham & Womens Hospital Inc : 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER
AU2007244927B2 (en) 2006-04-24 2012-01-12 Critical Care Diagnostics, Inc. Predicting mortality and detecting severe disease
EP2021796B1 (en) 2006-05-01 2012-02-08 Critical Care Diagnostics, Inc. Diagnosis of cardiovascular disease
PL2269063T3 (pl) 2008-04-18 2014-04-30 Critical Care Diagnostics Inc Rokowanie ryzyka głównych niekorzystnych zdarzeń sercowych
BR112012025728B1 (pt) 2010-04-09 2022-01-11 Critical Care Diagnostics, Inc Anticorpos isolados ou fragmentos que se liga a st2 humano solúvel, hibridoma, kit, bem como métodos para quantificação de um nível de st2 solúvel humano em uma amostra de um indivíduo, e para a predição do risco de morte dentro de um ano em um indivíduo
ES2750126T3 (es) 2011-03-17 2020-03-25 Critical Care Diagnostics Inc Procedimientos de predicción del riesgo de un resultado clínico adverso
DK2734222T3 (en) 2011-07-18 2017-01-30 Critical Care Diagnostics Inc PROCEDURES FOR TREATING CARDIOVASCULAR DISEASES AND PREDICTING THE EFFECTIVENESS OF MOTION THERAPY
CA2873896A1 (en) 2012-05-18 2013-11-21 Critical Care Diagnostics, Inc. Methods for treating or predicting risk of a ventricular tachyarrhythmia event
MX382403B (es) 2012-08-16 2025-03-13 Critical Care Diagnostics Inc Métodos para predecir el riesgo de desarrollar hipertensión.
CN104737170A (zh) 2012-08-21 2015-06-24 重症监护诊断股份有限公司 多标记风险分层
CA2935958A1 (en) * 2014-01-10 2015-07-16 Critical Care Diagnostics, Inc. Methods and systems for determining risk of heart failure
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
WO2017035639A1 (en) 2015-08-28 2017-03-09 Mcmaster University Method of determining risk of an adverse cardiac event
US20170220749A1 (en) * 2016-02-01 2017-08-03 MD Aware LLC Systems and methods for identifying and using medical calculators
JP6983223B2 (ja) * 2016-04-18 2021-12-17 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 一般集団におけるｌｖｈへの進行因子の同定のための可溶性ｓｔ２
WO2018220600A1 (en) * 2017-06-02 2018-12-06 University Of Florida Research Foundation, Inc. Method and apparatus for prediction of complications after surgery
RU2677611C1 (ru) * 2018-04-16 2019-01-17 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Способ прогнозирования неблагоприятных сердечно-сосудистых событий в течение 12 месяцев у больных хронической сердечной недостаточностью с рецидивом стенокардии после реваскуляризации миокарда
US12322100B2 (en) 2018-12-11 2025-06-03 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US12400762B2 (en) 2018-12-11 2025-08-26 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
EP3969620B1 (en) * 2019-05-17 2025-06-25 Regeneron Pharmaceuticals, Inc. Genome-based methods for reducing cardiovascular risk
CN118760892B (zh) * 2024-09-05 2024-11-19 温州市中心医院 铁死亡评分确定方法、系统及设备

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090264779A1 (en) * 2008-04-18 2009-10-22 Critical Care Diagnostics, Inc. Predicting risk of major adverse cardiac events
US20100267062A1 (en) * 2007-09-26 2010-10-21 Norbert Frey Osteopontin as Novel Prognostic Biomarker for Heart Failure
US20110137131A1 (en) * 2009-11-13 2011-06-09 Bg Medicine, Inc. Risk factors and prediction of myocardial infarction
US20120040381A1 (en) * 2006-04-24 2012-02-16 Snider James V Predicting mortality and detecting severe disease

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US5206140A (en) 1988-06-24 1993-04-27 Research Corporation Technologies, Inc. Assay for soluble crosslinked fibrin polymers
JPH0731479Y2 (ja) 1989-06-02 1995-07-19 内橋エステック株式会社 温度ヒューズ
US5217899A (en) 1990-08-24 1993-06-08 The General Hospital Corporation Cell stretching apparatus
JP2665850B2 (ja) 1991-11-14 1997-10-22 塩野義製薬株式会社 ｈＢＮＰのＣ端を認識するモノクロ−ナル抗体
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
JP2732005B2 (ja) 1992-12-14 1998-03-25 眞一 富永 ヒトｓｔ２をコードするｄｎａ、該ｄｎａの発現産物、該ｄｎａを発現させることによる発現産物の製造方法
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
CA2263832A1 (en) 1996-08-23 1998-02-26 Human Genome Sciences, Inc. T1 receptor-like ligand ii
WO1998038311A1 (en) 1997-02-28 1998-09-03 Human Genome Sciences, Inc. T1/st2-receptor ligand iii
ATE530180T1 (de) 1997-04-02 2011-11-15 Brigham & Womens Hospital Verfahren zur ermittlung der individualen risikoprofile atherosklerotischen erkrankungen
CA2293718A1 (en) 1997-06-10 1998-12-17 Medlyte Diagnostics, Inc. Methods for early detection of heart disease
CN1161609C (zh) 1997-09-11 2004-08-11 盐野义制药株式会社 哺乳类γ－BNP衍生物特异的免疫测定方法及其试剂盒
US6309888B1 (en) 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
GB9827348D0 (en) 1998-12-12 1999-02-03 Univ Leicester Natriuretic peptide
AU2055300A (en) 1998-12-18 2000-07-03 Scios Inc. Methods for detection and use of differentially expressed genes in disease states
WO2000073498A1 (en) 1999-06-02 2000-12-07 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
FR2795823B1 (fr) 1999-07-01 2001-11-23 Inst Nat Sante Rech Med Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial
US6323334B1 (en) 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
AU2001218871A1 (en) 2000-03-21 2001-10-03 Takao Arai Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
FR2807170B1 (fr) 2000-03-30 2002-06-28 Sipal Charniere elastique a frottement reduit
EP1311547A2 (en) 2000-08-22 2003-05-21 The Brigham And Women's Hospital, Inc. Diagnosis and treatment of cardiovascular conditions
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
US6537221B2 (en) 2000-12-07 2003-03-25 Koninklijke Philips Electronics, N.V. Strain rate analysis in ultrasonic diagnostic images
FI20010019L (fi) 2001-01-05 2002-07-06 Biohit Oyj Menetelmä atrofisen diagnostisoimiseksi
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US20040253637A1 (en) 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
ATE458199T1 (de) 2001-05-04 2010-03-15 Biosite Inc Diagnostische marker der akuten koronaren syndrome und ihre verwendungen
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
WO2003022987A2 (en) 2001-07-26 2003-03-20 Eos Biotechnology, Inc. Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
US6810284B1 (en) 2001-11-21 2004-10-26 Pacesetter, Inc. Implantable cardiac stimulation system and method for monitoring diastolic function
DK3072978T3 (en) 2002-05-09 2018-09-17 Brigham & Womens Hospital Inc : 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER
US8263325B2 (en) 2002-11-15 2012-09-11 Ottawa Heart Institute Research Corporation Predicting, detecting and monitoring treatment of cardiomyopathies and myocarditis
WO2004056868A2 (en) 2002-12-19 2004-07-08 Endocube Sas Nf-hev compositions and methods of use
US20040133079A1 (en) 2003-01-02 2004-07-08 Mazar Scott Thomas System and method for predicting patient health within a patient management system
US20040220155A1 (en) 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
US20050123451A1 (en) 2003-10-31 2005-06-09 Hiroshi Nomura System and apparatus for body fluid analysis using surface-textured optical materials
CA2547072C (en) 2003-11-26 2015-06-23 Applera Corporation Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof
EP2306192B1 (en) 2003-12-05 2015-10-14 The Cleveland Clinic Foundation Risk Markers For Cardiovascular Disease
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
JP2005291899A (ja) 2004-03-31 2005-10-20 Akira Matsumori 心疾患の検査法
EP1849009B1 (en) 2005-01-24 2008-10-29 F. Hoffmann-La Roche AG The use of cardiac hormones for assessing a cardiovascular risk with respect to the administration of anti-inflammatory drugs.
EP1731910A1 (en) 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
US20070021977A1 (en) 2005-07-19 2007-01-25 Witt Biomedical Corporation Automated system for capturing and archiving information to verify medical necessity of performing medical procedure
JP4820192B2 (ja) 2006-03-17 2011-11-24 一般財団法人化学及血清療法研究所 急性冠症候群でのａｄａｍｔｓ１３の測定と利用
ATE517341T1 (de) 2006-04-27 2011-08-15 Critical Care Diagnostics Inc Interleukin-33 (il-33) zur diagnose und vorhersage von herz-gefäss-erkrankungen
EP2021796B1 (en) * 2006-05-01 2012-02-08 Critical Care Diagnostics, Inc. Diagnosis of cardiovascular disease
PL2019965T3 (pl) 2006-05-02 2015-10-30 Critical Care Diagnostics Inc Rozpoznawanie różnicowe chorób układu oddechowego i sercowo-naczyniowego
US8147817B2 (en) 2006-05-04 2012-04-03 The Brigham And Women's Hospital, Inc. IL-33 in the treatment and diagnosis of diseases and disorders
RU2312591C1 (ru) 2006-06-14 2007-12-20 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" Способ прогнозирования развития риска внезапной смерти у больных с лево- и правожелудочковой экстрасистолией
CA2554659A1 (en) * 2006-07-25 2006-11-24 1128971 Alberta Ltd. Hanger flange for hanging a tubular body in a well
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
US20090111708A1 (en) * 2007-05-11 2009-04-30 Seddon Johanna M Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
FR2923029B1 (fr) 2007-10-26 2009-11-20 Minima Lunettes de type sans entourage a branches filaires
WO2009075566A1 (en) * 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Biomarkers for cardiovascular disease
US20100159474A1 (en) * 2008-11-11 2010-06-24 B.R.A.H.M.S. Aktiengesellschaft Prognosis and risk assessment in patients suffering from heart failure by determining the level of adm and bnp
JP2012531605A (ja) * 2009-07-01 2012-12-10 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 心血管死亡率リスクを予測するための方法
US8258456B2 (en) * 2009-11-27 2012-09-04 Himax Imaging, Inc. Image sensor
BR112012025728B1 (pt) 2010-04-09 2022-01-11 Critical Care Diagnostics, Inc Anticorpos isolados ou fragmentos que se liga a st2 humano solúvel, hibridoma, kit, bem como métodos para quantificação de um nível de st2 solúvel humano em uma amostra de um indivíduo, e para a predição do risco de morte dentro de um ano em um indivíduo
WO2012059477A1 (en) * 2010-11-01 2012-05-10 B.R.A.H.M.S Gmbh Prognosis and risk assessment of patients with non-specific complaints
RU2452394C1 (ru) 2010-11-09 2012-06-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Ульяновский государственный университет Способ прогнозирования риска смерти больных хронической сердечной недостаточностью
ES2750126T3 (es) 2011-03-17 2020-03-25 Critical Care Diagnostics Inc Procedimientos de predicción del riesgo de un resultado clínico adverso
DK2734222T3 (en) 2011-07-18 2017-01-30 Critical Care Diagnostics Inc PROCEDURES FOR TREATING CARDIOVASCULAR DISEASES AND PREDICTING THE EFFECTIVENESS OF MOTION THERAPY
CA2873896A1 (en) 2012-05-18 2013-11-21 Critical Care Diagnostics, Inc. Methods for treating or predicting risk of a ventricular tachyarrhythmia event
MX382403B (es) 2012-08-16 2025-03-13 Critical Care Diagnostics Inc Métodos para predecir el riesgo de desarrollar hipertensión.
CN104737170A (zh) 2012-08-21 2015-06-24 重症监护诊断股份有限公司 多标记风险分层
JP6178687B2 (ja) 2013-09-27 2017-08-09 富士機械工業株式会社 グラビア塗工装置
CA2935958A1 (en) 2014-01-10 2015-07-16 Critical Care Diagnostics, Inc. Methods and systems for determining risk of heart failure
USD770057S1 (en) 2014-04-14 2016-10-25 Critical Care Diagnostics, Inc. Blood test kit
US9934249B2 (en) 2014-06-03 2018-04-03 Conduent Business Machines Services, Llc Systems and methods for context-aware and personalized access to visualizations of road events
USD800332S1 (en) 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
USD800333S1 (en) 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120040381A1 (en) * 2006-04-24 2012-02-16 Snider James V Predicting mortality and detecting severe disease
US20100267062A1 (en) * 2007-09-26 2010-10-21 Norbert Frey Osteopontin as Novel Prognostic Biomarker for Heart Failure
US20090264779A1 (en) * 2008-04-18 2009-10-22 Critical Care Diagnostics, Inc. Predicting risk of major adverse cardiac events
US20120065897A1 (en) * 2008-04-18 2012-03-15 Snider James V Predicting risk of major adverse cardiac events
US20110137131A1 (en) * 2009-11-13 2011-06-09 Bg Medicine, Inc. Risk factors and prediction of myocardial infarction

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FDA: "Substantial Equivalence Determination Decision Summary Assay Only Template", 《FOOD AND DRUG ADMINISTRATION》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220399122A1 (en) * 2019-11-01 2022-12-15 Nec Corporation Risk prediction apparatus, risk prediction method, and computer program

Also Published As

Publication number Publication date
SG11201501271TA (en) 2015-03-30
US10741290B2 (en) 2020-08-11
EP2888687B1 (en) 2023-08-02
HK1212057A1 (en) 2016-06-03
CN111834009A (zh) 2020-10-27
IN2015DN01767A (https=) 2015-05-29
JP2015532715A (ja) 2015-11-12
US20190237197A1 (en) 2019-08-01
RU2015110054A (ru) 2016-10-10
JP6621520B2 (ja) 2019-12-18
CA2882303A1 (en) 2014-02-27
JP6450679B2 (ja) 2019-01-09
JP2020034573A (ja) 2020-03-05
AU2021202116A1 (en) 2021-05-06
AU2013305829A1 (en) 2015-03-05
US10303844B2 (en) 2019-05-28
JP6902083B2 (ja) 2021-07-14
MX375520B (es) 2025-03-06
AU2019201709A1 (en) 2019-04-04
HK1208092A1 (en) 2016-02-19
JP2019053086A (ja) 2019-04-04
MX2020009943A (es) 2020-10-16
EP2888687A1 (en) 2015-07-01
WO2014031764A1 (en) 2014-02-27
US20170169179A1 (en) 2017-06-15
US20140058743A1 (en) 2014-02-27
US20200335220A1 (en) 2020-10-22
EP2888687A4 (en) 2016-04-13
AU2019201709B2 (en) 2021-01-07
MX2015002254A (es) 2015-05-08
SG10201608854TA (en) 2016-12-29

Similar Documents

Publication Publication Date Title
US10741290B2 (en) Multimarker risk stratification
Wussler et al. Clinical utility of procalcitonin in the diagnosis of pneumonia
JP6788050B2 (ja) 主要有害心イベントのリスクを予測する方法
Oudejans et al. Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests
US11404166B2 (en) Systems and methods for mining of medical data
US11162955B2 (en) System and method for determining risk of diabetes based on biochemical marker analysis
Kanagala et al. Plasma Tenascin-C: a prognostic biomarker in heart failure with preserved ejection fraction
Huang et al. Development and validation of a nomogram to predict the risk of death within 1 year in patients with non-ischemic dilated cardiomyopathy: a retrospective cohort study
US20170205420A1 (en) Biochemical markers for use in determining risk of diabetes
Mavrea et al. Causes and predictors of hospital readmissions in patients older than 65 years hospitalized for heart failure with preserved left ventricular ejection fraction in western Romania
Kallis et al. The relationship between cardiac troponin in people hospitalised for exacerbation of COPD and major adverse cardiac events (MACE) and COPD readmissions
Arın Prognostic Value of a Low-Cost LDH–Hemoglobin–Albumin Biomarker Panel in Acute Heart Failure: A Real-World Cohort from a Resource-Limited Setting
Kurtinecz B-type and N-terminal Pro-B-type Natriuretic Peptides in Heart Failure
HK40005186A (en) System and method for determining risk of diabetes based on biochemical marker analysis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1212057

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150624

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1212057

Country of ref document: HK